Thomas J. Galloway, MD

Thomas Galloway, MD

Request an Appointment

Call 888-369-2427

Request Online

Clinical Locations

  • Fox Chase Cancer Center
    333 Cottman Avenue
    Philadelphia, PA 19111
    Phone: 888-369-2427

Professor, Department of Radiation Oncology

Chief, Division of Head and Neck Radiation Oncology

Medical Director, Clinical Research

Specialties

  • Radiation Oncology ; 
  • Head and Neck Radiation Oncology

Areas of Expertise

Head & Neck Cancer, Thyroid Cancer, Skin Cancer, Melanoma

Treatment Focus

  • Intensity modulated radiation therapy
  • Stereotactic body radiation therapy
  • Modulated electron beam therapy
  • Interstitial brachytherapy
  • Rotational arc therapy

Research Program

Distinctions

Treatment Philosophy

I joined Fox Chase after completing my residency at the University of Florida in 2010. I specialize in treating cancers of the head and neck and skin cancer.

Cancer is a complicated, confusing diagnosis. Cancers of the head and neck are particularly challenging because they occur in areas that can affect our ability to perform some of our most basic functions: breathing, speaking, and eating.

I came to Fox Chase because I believe that the best way to cure these difficult cancers while maintaining quality of life is through a multi-disciplinary approach. Some cancers are cured with radiation alone, some need the assistance of both surgery and chemotherapy, and some are cured without radiation. The team approach at Fox Chase ensures that many different disciplines are working together to decide the best treatment for your unique case with one unifying goal: curing your cancer while avoiding unnecessary toxicity

Educational Background

  • MD, University of Florida, Gainesville, FL, 2005
  • BS, Chemistry, University of Florida, Gainesville, FL, 2001

Certifications

  • American Board of Radiology - Radiation Oncology

Memberships

  • American Society of Therapeutic Radiology (ASTRO)
  • Radiation Therapy Oncology Group (RTOG)
  • Institutional Principal Investigator for Fox Chase Cancer Center (Institution 2212) July 2013 - Present
  • American Radium Society (ARS)
  • Radiological Society of North America (RSNA)
  • American College of Radiology (ACR)
  • Eastern Cooperative Oncology Group (ECOG)

    Honors & Awards

    • Philadelphia Magazine Top Doctors, 2018-20, 2023-2024
    • ARRO Educator of the year, Fox Chase Cancer Center 2013
    • Practical Radiation Oncology, Certificate in Excellence of Reviewing, 2013

    Research Interests

    • Head and neck cancer
    • Head and neck cancer survivorship
    • Skin Cancer (both melanoma and non-melanoma)
    • Merkel Cell Carcinoma Radiation target delineation
    • Pre-treatment imaging evaluation beyond the diagnosis
    • Impact of time to treatment in the curative management of head and neck cancer

    Selected Publications

    Ebersole B., McCarroll L., Ridge J.A., Liu J.C., Bauman J., Donnelly S., Galloway T.J., Identification and management of late dysfunction in survivors of head and neck cancer: Implementation and outcomes of an interdisciplinary quality of life (iqol) clinic. Head Neck. 43(7): 2124-2135, 2021. https://www.ncbi.nlm.nih.gov/pubmed/33749012.

    Lee C.T., Galloway T.J., Pathogenesis and amelioration of radiation-induced oral mucositis. Curr Treat Options Oncol. 23(3): 311-324, 2022. PMC8931694. https://www.ncbi.nlm.nih.gov/pubmed/35244887.

    Murphy CT, Galloway TJ, Handorf EA, Wang L, Mehra R, Flieder D, Ridge JA. The Survival Impact of Increasing Time to Treatment Initiation for Patients with Head and Neck Cancer in the United States. Accepted for publication in Journal of Clinical Oncology PubMed

    Murphy CT, Devarajan K, Wang LS, Mehra R, Ridge JA, Fundakowski C, Galloway TJ. Pre-Treatment Tumor-Specific Growth Rate as a Temporal Biomarker that Predicts Treatment Failure and Improves Risk Stratification for Oropharyngeal Cancer. Accepted for publication in Oral Oncology PubMed

    Lango MN, Galloway TJ, Mehra R, Ebersole B, Liu JC, Burtness B, Moran K, Ridge JA.  Impact of baseline dysphagia on acute feeding tube placement in head and neck cancer patients undergoing definitive radiation.  Epub ahead of print in Head and Neck PubMed

    Galloway TJ, Ridge JA.  Management of squamous cancer metastatic to cervical nodes with unknown primary.  Epub ahead of print in Journal of Clinical Oncology PubMed

    Galloway TJ, Wirth L, Colevas D, Gilbert J, Bauman J, Saba N, Raben D, Mehra R, Burtness B, Jimeno A. A Phase 1 Study of CUDC-101, a multitarget inhibitor of HDACs, EGFR and HER2, in combination with chemoradiation in patients with head and neck squamous cell carcinoma (Clinical Cancer Research 2015; 21(7) 1566-1573). PubMed

    Murphy CT, Galloway TJ, Handorf EA, Wang L, Mehra R, Flieder D, Ridge JA. Increasing time to treatment initiation for squamous cell carcinoma of the head and neck: An analysis of the National Cancer Database. (Cancer 2015; 121(8) 1204-1213). PubMed

    Nguyen-Tan PF, Zhang QE, Ang KK, Wheeler RH, Weber RS, Rosenthal DI, Bahary JP, Kim H, Silverman C, Raben A, Galloway T, Vigneault E, Gore E, Westra WH, Chung CH, Jordan RC, Gillison ML, List M, Le QT. A Randomized Phase III Trial to Test Accelerated versus Standard Fractionation in Combination with Concurrent Cisplatin for Head and Neck Carcinomas (RTOG 0129): Long Term Report of Efficacy and Toxicity. (Journal of Clinical Oncology 2014; 32(34) 3858-3867 

    Lango MN, Egleston B, Fang CY, Burtness B, Galloway T, Liu JC, Mehra R, Ebersole B, Moran KM, Ridge JA. Baseline Health Perceptions, weight-loss and survival in head and neck cancer. (Cancer 2014; 120(6):840-7

    ... Expand

    Additional Publications

    My NCBI

    Resize Text

    Related Articles

    00 / 00